US 12,329,814 B2
Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer
Gwanghee Lee, Busan (KR); Jeonghyun Ryou, Gyeonggi-do (KR); Jiwon Huh, Seoul (KR); Tadatsugu Taniguchi, Tokyo (JP); Sho Hangai, Tokyo (JP); and Hideyuki Yanai, Tokyo (JP)
Assigned to Boostimmune, Inc., Seoul (KR); and THE UNIVERSITY OF TOKYO, Tokyo (JP)
Filed by Boostimmune, Inc., Seoul (KR); and The University of Tokyo, Tokyo (JP)
Filed on Jun. 30, 2022, as Appl. No. 17/854,739.
Prior Publication US 2024/0000932 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method for treating cancer in a patient in need thereof, comprising administering a combination comprising (1) a substance that suppresses or inhibits a function of extracellular translationally controlled tumor protein (TCTP) or its modified form, or a fragment or multimer thereof and (2) a cancer immunotherapeutic agent, to the patient,
wherein the substance that suppresses or inhibits the function of extracellular TCTP or its modified form, or a fragment or multimer thereof is an antibody or antigen-binding fragment thereof which specifically binds to TCTP or its modified form, or a fragment or multimer thereof, and the extracellular TCTP or its modified form, or a fragment or multimer thereof has been released from tumor cells,
wherein the cancer immunotherapeutic agent is an immune checkpoint inhibitor selected from an anti-PD-1 antibody and anti-CTLA-4 antibody, and
wherein the antibody or antigen-binding fragment thereof, which specifically binds to TCTP or its modified form, or a fragment or multimer thereof, and the extracellular TCTP or its modified form, or a fragment or multimer thereof, comprises complementarity-determining region (CDR)-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 selected from the group consisting of the following:
a) CDR-H1 of the sequence of SEQ ID NO: 1, CDR-H2 of the sequence of SEQ ID NO: 2, CDR-H3 of the sequence of SEQ ID NO: 3; CDR-L1 of the sequence of SEQ ID NO: 4, CDR-L2 of the sequence of SEQ ID NO: 5, and CDR-L3 of the sequence of SEQ ID NO: 6;
b) CDR-H1 of the sequence of SEQ ID NO: 7, CDR-H2 of the sequence of SEQ ID NO: 8, CDR-H3 of the sequence of SEQ ID NO: 9; CDR-L1 of the sequence of SEQ ID NO: 10, CDR-L2 of the sequence of SEQ ID NO: 11, and CDR-L3 of the sequence of SEQ ID NO: 12;
c) CDR-H1 of the sequence of SEQ ID NO: 13, CDR-H2 of the sequence of SEQ ID NO: 14, CDR-H3 of the sequence of SEQ ID NO: 15; CDR-L1 of the sequence of SEQ ID NO: 16, CDR-L2 of the sequence of SEQ ID NO: 17, and CDR-L3 of the sequence of SEQ ID NO: 18; and
d) CDR-H1 of the sequence of SEQ ID NO: 19, CDR-H2 of the sequence of SEQ ID NO: 20, CDR-H3 of the sequence of SEQ ID NO: 21; CDR-L1 of the sequence of SEQ ID NO: 22, CDR-L2 of the sequence of SEQ ID NO: 23, and CDR-L3 of the sequence of SEQ ID NO: 24.